Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07408830 · ClinicalTrials.gov registry record · NA
VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors
A NA study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- NA
- Development phase
- 2,482
- Enrollment target
NCT07408830: Clinical Trial NA study, sponsored by VA Office of Research and Development.
NCT07408830 is a NA study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 2,482 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07408830, a NA study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 2,482 participants
- Enrollment target
Study Summary
CSP #2036 is a pragmatic, randomized, intent-to-treat, two-arm, parallel, multicenter CSP trial. Blinding of clinical staff and participants will not be possible. However, outcomes will be adjudicated by assessors blinded to randomization arm to minimize bias. Due to the pragmatic nature of the study, treatment for bladder cancer will be at the discretion of the VA participants' clinicians, and all treatments will be recorded. Veterans with high-grade non-muscle invasive bladder cancer who underwent biopsy or transurethral resection of a bladder tumor (TURBT) in the prior 6 months will be invited to participate. After a normal first cystoscopy after TURBT (also known as "3-month cystoscopy") and additional screening, participants will be randomized 1:1 to a program of low- vs high-intensity surveillance. Stratification by stage (2 groups: Ta only vs. any T1 / any Carcinoma in situ), and site will be done because these may influence other bladder cancer-specific care, such as the threshold of when to biopsy a possible bladder lesion and whether to administer intravesical therapy. Outcomes will be assessed during study visits every three months for 24 months, every six months after that up to 48 months, and at 60 months. Follow-up data collection beyond 60 months will be completed by phone call or participants' health record review. This will be a 10-year study with 6 years dedicated to recruitment and a minimum of 4 years dedicated to follow-up. Thus, estimated average follow-up will be 7 years and maximum follow-up will be 10 years.
Primary Outcome
Time to death will be calculated from the most recent bladder biopsy or resection showing urothelial carcinoma prior to enrollment.
Interventions
- OTHER Low Intensity Surveillance
- OTHER High Intensity Surveillance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,482 participants |
| Start Date | 2027-01-01 |
| Est. Completion | 2037-01-01 |
| Phase | NA |
What is known before NCT07408830 opens enrollment
NCT07408830 is an interventional study that assigns participants to a tested intervention. Its 2,482 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% higher).
The record links to 0 conditions, and to 2 interventions - of which Low Intensity Surveillance is the first listed.
NCT07408830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07408830 about?
NCT07408830 is a clinical study titled "VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors". CSP #2036 is a pragmatic, randomized, intent-to-treat, two-arm, parallel, multicenter CSP trial. Blinding of clinical staff and participants will not be possible. However, outcomes will be adjudicated by assessors blinded to randomization arm to minimize bias. Due to the pragmatic nature of the stud...
What is the current status of trial NCT07408830?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 2,482 participants. The study started on 2027-01-01. Estimated completion is 2037-01-01.
What interventions are being tested in trial NCT07408830?
The interventions under investigation include: Low Intensity Surveillance (OTHER), High Intensity Surveillance (OTHER).
Who is sponsoring clinical trial NCT07408830?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07408830's enrollment target sits among peer trials
2,482 45th of 2000 higher than 1,956 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI